253 related articles for article (PubMed ID: 21717996)
1. Locally administered zoledronic Acid therapy for giant cell tumor of bone.
Nishisho T; Hanaoka N; Endo K; Takahashi M; Yasui N
Orthopedics; 2011 Jul; 34(7):e312-5. PubMed ID: 21717996
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone.
Gouin F; Rochwerger AR; Di Marco A; Rosset P; Bonnevialle P; Fiorenza F; Anract P
Eur J Cancer; 2014 Sep; 50(14):2425-31. PubMed ID: 25088085
[TBL] [Abstract][Full Text] [Related]
3. Local administration of zoledronic acid for giant cell tumor of bone.
Nishisho T; Hanaoka N; Miyagi R; Sakai T; Toki S; Takahashi M; Kenji E; Yasui N; Sairyo K
Orthopedics; 2015 Jan; 38(1):e25-30. PubMed ID: 25611416
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid-loaded bone cement as a local adjuvant therapy for giant cell tumor of the sacrum after intralesional curettage.
Chen KH; Wu PK; Chen CF; Chen WM
Eur Spine J; 2015 Oct; 24(10):2182-8. PubMed ID: 25940568
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone.
Cheng YY; Huang L; Lee KM; Xu JK; Zheng MH; Kumta SM
Calcif Tissue Int; 2004 Jul; 75(1):71-7. PubMed ID: 15037971
[TBL] [Abstract][Full Text] [Related]
6. Factors of local recurrence of giant cell tumor of long bone after treatment: plain radiographs, pathology and surgical procedures.
Chanchairujira K; Jiranantanakorn T; Phimolsarnti R; Asavamongkolkul A; Waikakul S
J Med Assoc Thai; 2011 Oct; 94(10):1230-7. PubMed ID: 22145509
[TBL] [Abstract][Full Text] [Related]
7. Giant cell tumour of bone in the denosumab era.
van der Heijden L; Dijkstra PDS; Blay JY; Gelderblom H
Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: a case report and review of the literature.
Arpornchayanon O; Leerapun T
J Med Assoc Thai; 2008 Oct; 91(10):1609-12. PubMed ID: 18972907
[TBL] [Abstract][Full Text] [Related]
9. [Clinical studies on effect of bone cement filling on articular cartilage of the knee after curettage of giant cell tumor].
Cao W; Ye Z; Lin N; Liu M
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2014 Dec; 28(12):1459-63. PubMed ID: 25826886
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.
Balke M; Campanacci L; Gebert C; Picci P; Gibbons M; Taylor R; Hogendoorn P; Kroep J; Wass J; Athanasou N
BMC Cancer; 2010 Aug; 10():462. PubMed ID: 20799989
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
[TBL] [Abstract][Full Text] [Related]
12. Local recurrence after curettage treatment of giant cell tumors in peripheral bones: retrospective study by the GSF-GETO (French Sarcoma and Bone Tumor Study Groups).
Gouin F; Dumaine V;
Orthop Traumatol Surg Res; 2013 Oct; 99(6 Suppl):S313-8. PubMed ID: 23978709
[TBL] [Abstract][Full Text] [Related]
13. Malignant transformation of a giant cell tumor 25 years after initial treatment.
Mori Y; Tsuchiya H; Karita M; Nonomura A; Nojima T; Tomita K
Clin Orthop Relat Res; 2000 Dec; (381):185-91. PubMed ID: 11127655
[TBL] [Abstract][Full Text] [Related]
14. Mid-term outcome after curettage with polymethylmethacrylate for giant cell tumor around the knee: higher risk of radiographic osteoarthritis?
van der Heijden L; van de Sande MA; Heineken AC; Fiocco M; Nelissen RG; Dijkstra PD
J Bone Joint Surg Am; 2013 Nov; 95(21):e159. PubMed ID: 24196471
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Tumor of Bone: A 1 to 12-Year Follow-up Study.
Greenberg DD; Lee FY
Am J Clin Oncol; 2019 Mar; 42(3):231-237. PubMed ID: 30811352
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma.
Zhou Z; Guan H; Duan X; Kleinerman ES
Cancer; 2005 Oct; 104(8):1713-20. PubMed ID: 16121404
[TBL] [Abstract][Full Text] [Related]
17. Regression of giant cell tumor of the cervical spine with bisphosphonate as single therapy.
Gille O; Oliveira Bde A; Guerin P; Lepreux S; Richez C; Vital JM
Spine (Phila Pa 1976); 2012 Mar; 37(6):E396-9. PubMed ID: 22076646
[TBL] [Abstract][Full Text] [Related]
18. Giant cell rich osteosarcoma revisited-diagnostic criteria and histopathologic patterns, Ki67, CDK4, and MDM2 expression, changes in response to bisphosphonate and denosumab treatment.
Chow LT
Virchows Arch; 2016 Jun; 468(6):741-55. PubMed ID: 27003154
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate therapy is effective in the treatment of sacral giant cell tumor.
Chaudhary P; Khadim H; Gajra A; Damron T; Shah C
Onkologie; 2011; 34(12):702-4. PubMed ID: 22156450
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
